Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 63Recruiting 24Unknown 22Terminated 6Not yet recruiting 5Active not recruiting 5Withdrawn 3Enrolling by invitation 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Colonic Neoplasms 2Rectal Neoplasms 1Pancreatic Neoplasms 1Colorectal Cancer Metastatic 1

Interventions

Oxaliplatin 20Fluorouracil 20Leucovorin 19Bevacizumab 16Cetuximab 13Irinotecan 12Capecitabine 8regorafenib 5Radiotherapy 5Nivolumab 5Drug Therapy 5aflibercept 4Radiosurgery 4Neoadjuvant Therapy 4Magnetic Resonance Spectroscopy 4Chemotherapy, Adjuvant 4Biopsy 4pembrolizumab 3durvalumab 3atezolizumab 3Specimen Handling 3Folfox protocol 3Cyclophosphamide 3trifluridine tipiracil drug combination 2tremelimumab 2tislelizumab 2poly(I).poly(c12,U) 2futuximab 2fludarabine 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Colorectal Neoplasms × Folfox protocol × Clear all
NCT07323576 2026-02-09

INAVO-CRC

Hoffmann-La Roche

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT04145193 2020-09-21

Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC

MedImmune LLC

Phase 2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT01786538 2013-03-13

Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines

Asan Medical Center

Phase 3 Withdrawn
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡